Penfluridol for relapsed small cell cancers
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a pill called penfluridol for people with small cell lung or cervical cancer that has come back or not gotten better after at least two prior treatments. Penfluridol is a drug that may help stop cancer cells from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have small cell lung cancer or small cell cervical cancer that has returned or not responded to at least two previous treatments, including etoposide and platinum chemo.
- You are able to do most of your daily activities (ECOG 0 or 1).
- You have at least one tumor that can be measured on a CT or MRI scan.
- Your kidney, liver, and blood cell counts are within safe ranges, and you are not pregnant (if applicable).
- You have not had recent chemotherapy, targeted therapy, or radiation within the required waiting period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial tests whether adding immunotherapy (durvalumab) to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. It is for people who have had their cancer completely removed and are well enough to start treatment soon after surgery.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
This trial tests different treatments based on the genetic and molecular features of your tumor. It is for people with stage IV small cell lung cancer that has returned after initial chemotherapy.
This study tests a new drug called BMS-986525, alone or with other treatments, for people with small cell lung cancer that has come back or not responded to treatment. It aims to find out if the drug is safe and tolerable.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Hear when a new Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.